Dianthus director sells 2,778 shares after option exercise
Dianthus Therapeutics, Inc. (DNTH) director Simon Read reported an option exercise-and-sale on common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dianthus Therapeutics, Inc. (DNTH) director Simon Read reported an option exercise-and-sale on common stock. He exercised 2,778 stock options at an exercise price of $18.36 per share, acquiring 2,778 shares of common stock, and on the same date sold 2,778 shares at a weighted-average price of $117.55 per share. The option exercise left 19,445 options reported as outstanding after the transaction, with the option expiring on May 22, 2035. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026, and the option award vests in three equal annual installments, subject to continued service.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,778 shares ($276K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Read Simon
Role
Director
Sold
2,778 shs ($327K)
Approx. gross sale proceeds
$327K
Approx. exercise cost
$51K
Approx. pre-tax spread
$276K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 2,778 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,778 | $18.36 | $51K |
| Sale | Common Stock F1, F2 | 2,778 | $117.55 | $327K |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,445 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options Exercised: 2,778 shares
Option Exercise Price: $18.36 per share
Shares Sold: 2,778 shares
+4 more
7 metrics
Options Exercised
2,778 shares
Stock options exercised into common stock on August 19, 2026
Option Exercise Price
$18.36 per share
Exercise price for stock options converted into 2,778 common shares
Shares Sold
2,778 shares
Common stock sold following option exercise on August 19, 2026
Weighted-Average Sale Price
$117.55 per share
Weighted-average price for 2,778 common shares sold, within $117.01–$117.66 range
Remaining Options
19,445 options
Total stock options reported as held after the partial exercise
Option Expiration Date
May 22, 2035
Expiration of the stock option award from which 2,778 options were exercised
Rule 10b5-1 Plan Adoption Date
May 8, 2026
Adoption date of trading plan governing the reported transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock option, vesting
4 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option financial
"The shares of common stock underlying this stock option award vest"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"underlying this stock option award vest as to one-third of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Simon Read report for Dianthus Therapeutics (DNTH)?
Simon Read reported exercising 2,778 stock options at $18.36 per share and selling 2,778 common shares at a weighted-average price of $117.55 per share. These transactions occurred on August 19, 2026, as part of an exercise-and-sale sequence.
How many Dianthus Therapeutics (DNTH) options does Simon Read report remaining after this transaction?
After exercising part of his award, Simon Read reports 19,445 stock options remaining outstanding. These options relate to a grant expiring on May 22, 2035, with the underlying shares of common stock subject to a three-year vesting schedule.
Were Simon Read’s DNTH trades made under a Rule 10b5-1 plan?
Yes, the filing states the trades were effected under a Rule 10b5-1 trading plan adopted on May 8, 2026. Such pre-arranged plans allow insiders to schedule trades in advance, helping manage trading while limiting discretion over timing.
What is the vesting schedule of the DNTH stock options involved in this Form 4?
The options vest in three equal installments, with one-third of the shares vesting on each of the first, second, and third anniversaries of the grant date. Vesting is conditioned on the reporting person’s continued service to Dianthus Therapeutics on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
